Drug lookup | Fillwise

METOCLOPRAMIDE HCL

All products: not a benefit

Other products in the same Health Canada class (A03FA) — coverage varies; not interchangeable

Domperidone (Motilium): general benefit, Not a benefit

Maxeran · DIN 02099209 · 10mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2000-07-28 — choose a marketed DIN from the same-category list.Discontinued 2000-07-28 · checked 2026-09-19

StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2000-07-28 — choose a marketed DIN from the same-category list.

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2000-07-28 — choose a marketed DIN from the same-category list.

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Maxeran · DIN 02099209 Manufacturer: Hoechst Marion Roussel Canada Inc.; listing date 1996-10-01 Health Canada: Cancelled post market since 2000-07-28 · brand MAXERAN-10 (10MG TABLET) · ATC A03FA01 METOCLOPRAMIDE · form Tablet · route Oral · ingredients METOCLOPRAMIDE HYDROCHLORIDE 10 MG/TAB · company Hoechst marion roussel canada inc. · schedule Prescription

Check this DIN again · Health Canada product record

Maxeran: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18226 · Verify on the e-Formulary ↗ (DIN 02099209)

Source record

DIN 02099209: Maxeran Raw flags: notABenefit=Y, sec3=Y Item: 564000005; group id 684; item number 1703; lccId None; manufacturer id HMR Source form: Tab; strength: 10mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02099209 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18226

Interchangeable products

PRZ-Metoclopramide · DIN 02548755 · $0.1513

Shortage status: not checked (no credentials)

Health Canada lists this DIN as Cancelled post market since 2000-07-28 — choose a marketed DIN from the same-category list.

Other drugs in the same formulary class (56:40 Miscellaneous G.I. Drugs) and how they are covered

Matched class: 56:40 Miscellaneous G.I. Drugs

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: BUDESONIDE, MESALAZINE, NIZATIDINE, OLSALAZINE SODIUM, PANTOPRAZOLE MAGNESIUM, RABEPRAZOLE SODIUM, SUCRALFATE Some products covered without a code (check the product listing): 5-AMINOSALICYLIC ACID, CIMETIDINE, DOMPERIDONE MALEATE, FAMOTIDINE, LACTULOSE, MISOPROSTOL, RANITIDINE HCL 56:40 Miscellaneous G.I. Drugs

DOMPERIDONE MALEATE

· 11 products · Listed, not a benefit (1), General benefit (10) · strengths: 10mg · Tab

5-AMINOSALICYLIC ACID

· 17 products · General benefit (16), Listed, not a benefit (1) · strengths: 1g/Actuation, 500mg, 1.2g, 1g, 1g/100mL, 4g/100mL, 4g, 1000mg, 400mg · 14 Actuation-Foam Enema Canister Pk, Del-Release Tab, Delayed & ER Tab, DR Tab, Enema, Ent Tab, ER Tab, Rect Susp-Pk, Sup, Tab

BUDESONIDE

· 1 products · General benefit · strengths: 2mg/Act · Rectal Foam-14 Act Canister

CIMETIDINE

· 10 products · General benefit (5), Listed, not a benefit (5) · strengths: 200mg, 300mg, 400mg, 600mg, 800mg · Tab

FAMOTIDINE

· 16 products · Listed, not a benefit (2), General benefit (14) · strengths: 20mg, 40mg · Tab

LACTULOSE

· 7 products · General benefit (6), Listed, not a benefit (1) · strengths: 667mg/mL · O/L

MESALAZINE

· 2 products · General benefit · strengths: 800mg, 1600mg · DR Tab

MISOPROSTOL

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 100mcg, 200mcg · Tab

NIZATIDINE

· 2 products · General benefit · strengths: 150mg, 300mg · Cap

OLSALAZINE SODIUM

· 1 products · General benefit · strengths: 250mg · Cap

PANTOPRAZOLE MAGNESIUM

· 6 products · General benefit · strengths: 40mg · Ent Coated Tab

RABEPRAZOLE SODIUM

· 16 products · General benefit · strengths: 10mg, 20mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 56:40 and 10 more

Full class listing Related classes: 56:04 Antacids and Adsorbents, 56:08 Antidiarrhea Agents, 56:12 Cathartics, 56:16 Digestants, 56:22 Antiemetics and Antinauseants Same formulary class, not same indication: class membership alone does not establish equivalent uses.

What the Health Canada label says it is for

INDICATIONS AND CLINICAL USE Metoclopramide Hydrochloride Injection Page 2 of 18 Metoclopramide Hydrochloride Injection is useful as an adjunct in the management of delayed gastric emptying associated with subacute and chronic gastritis and sequelæ of surgical operations such as vagotomy and pyloroplasty. Metoclopramide Hydrochloride Injection is indicated in the prophylaxis of vomiting induced by cancer chemotherapeutic regimens that include cisplatin as a component. Metoclopramide Hydrochloride Injection has been found useful as an adjunct to facilitate small bowel intubation. Metoclopramide Hydrochloride Injection is indicated for the prophylaxis of postoperative vomiting. https://pdf.hres.ca/dpd_pm/00032319.PDF PM date: November 18, 2014 Source product: METOCLOPRAMIDE HYDROCHLORIDE INJECTION; DIN 02185431; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Maxeran: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote

Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote

Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026